Tag: shroom boom
-
Today’s Idea: Filament Health (FH.NE) Is All Natural
Natural Talent Albert Hofmann was a fun guy, pun intended. More importantly, the Swiss chemist is known for being the first person to synthesize, consume, and learn of the psychedelic effects of lysergic acid diethylamide (LSD). Truly a mad chemist. Furthermore, Hofmann was also the first person to isolate, synthesize, and name the principal psychedelic compounds…
-
Pure Extracts (PULL.C) to enter U.S. market through JV in Michigan
If the LOI becomes a binding contract, Pure Extracts will contribute “a mix of equipment and cash to the venture”, which will allow the partners to rapidly scale-up to meet the rising demand for recreation cannabis concentrates and edibles throughout Michigan.
-
Revive Therapeutics (RVV.C) CEO Michael Frank likes the stock, buys the dip
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an alarm or anything, things have been running pretty nicely the past couple of quarters and it was probably time for a correction. Any time a sector emerges this quickly there…
-
Pure Extracts (PULL.C) submits 20 SKUs to Health Canada, based on its proprietary CO2 extraction technology
PULL submitted over 20 Stock Keeping Units (SKU) product identifiers for approval including THC vapes, CBD vapes, 1:1 blended vapes, and 3 different flavours/formulations of gummies.
-
Pure Extracts (PULL.C) cuts a licensing deal with Taste-T, the maker of Fireball Cannabis Gummies
Included in the agreement is the delivery to Pure Extracts’ British Columbia facility of one of Taste-T’s custom built gummie-manufacturing machines, certified to Canadian standards.
-
Pure Extracts (PULL.C) begins mushroom build-out
Pure Extracts is targeting the commercial cannabis and psychedelics sector, backed by deep extraction and production expertise.
-
Revive Therapeutics (RVV.C) finds pharma asset under the couch that may treat COVID-19
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business. Miners become weed companies, then biotech companies, then shroom companies, as boards and management pursue new opportunities that might one day prove better than the last.